Publications by authors named "A Imaz"
Background: In patients with hepatitis C virus (HCV) chronic infection and advanced liver disease, the impact of human immunodeficiency virus (HIV) coinfection on the clinical outcome after sustained virological response (SVR) has not been sufficiently clarified. The aim of this study was to compare the mortality after SVR of patients bearing HCV chronic infection and advanced liver fibrosis, with and without HIV-coinfection after a prolonged follow-up.
Methods: This was a prospective multicenter cohort study including individuals with HIV/HCV-coinfection and patients with HCV-monoinfection from Spain, fulfilling: 1) Liver stiffness (LS) ≥9.
Article Synopsis
- A study was conducted to create a risk score to predict loss to follow-up (LTFU) in patients living with HIV (PLWH) in Catalonia and the Balearic Islands.
- The study analyzed 6,661 PLWH and identified key factors contributing to LTFU, including age, nationality, drug use, viral load, and time since diagnosis.
- The results indicated that a significant portion of PLWH (28.8%) was at medium risk and 3.4% at high risk for LTFU, highlighting the need for targeted interventions to retain patients in HIV care.
Introduction And Objectives: The HepHIV 2023 Conference, held in Madrid in November 2023, highlighted how Europe is not on track to meet the United Nations (UN) sustainable development goals and Joint UN Programme on HIV/AIDS (UNAIDS) targets. This article presents the outcomes of the conference, which focus on ways to improve testing and linkage to care for HIV, viral hepatitis, and other sexually transmitted infections. HIV-related stigma and discrimination, a major barrier to progress, was a key concept of the conference and on the agenda of the Spanish Presidency of the European Union.
View Article and Find Full Text PDFIntroduction: Antiretroviral therapy (ART) can be personalized through simple formulations with high resistance barriers, favorable safety profiles, and novel administration routes. Switching treatments has become a key clinical strategy for addressing drug toxicity and interactions and enhancing adherence and convenience. This strategy aims to improve the quality of life and long-term efficacy, even in challenging cases like people living with HIV (PLWH) with multiple comorbidities, prior virological failure, and drug resistance.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the effects of drug-drug interactions (DDIs) between antiretrovirals (ARVs) and other medications, including over-the-counter (OTC) drugs, on treatment outcomes in real-world settings.
- Between March 2019 and May 2023, 139 clinical cases were reviewed, revealing that most interactions involved common ARV boosters and highlighted frequent DDI issues with CNS and cardiovascular drugs as well as OTC medications.
- The findings emphasize the need for careful medication reconciliation, as OTC drugs often led to reduced efficacy of ARVs and toxicity in certain cases, making real-world case data a vital tool for understanding DDIs in clinical practice.